期刊
ACS NANO
卷 16, 期 9, 页码 13992-14006出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.2c03597
关键词
extracellular vesicles; aggregation-induced emission; dendritic cells; immunotherapy; exocytosis
类别
资金
- National Key Rese arch and Deve lopment Pro gram of China [2020YFA0803700]
- National Natural Science Foundation of China [81830060, 81971670, 52173285]
A strategy is developed to generate DEV-AIE nanoparticles by using DCs as a cell reactor, enabling synergistic photodynamic immunotherapy for effective tumor treatment and inhibition of cancer stem cells.
Dendritic cell (DC)-derived small extracellular vesicles (DEVs) are recognized as a highly promising alternative to DC vaccines; however, the clinical testing of DEV-based immunotherapy has shown limited therapeutic efficacy. Herein, we develop a straightforward strategy in which DCs serve as a cell reactor to exocytose high-efficient DEV-mimicking aggregation-induced emission (AIE) nanoparticles (DEV-AIE NPs) at a scaled-up yield for synergistic photodynamic immunotherapy. Exocytosed DEV-AIE NPs inherit not only the immune-modulation proteins from parental DCs, enabling T cell activation, but also the loaded AIE-photosensitizer MBPN-TCyP, inducing superior immunogenic cell death (ICD) by selectively accumulating in the mitochondria of tumor cells. Eventually, DEV-AIE synergistic photodynamic immunotherapy elicits dramatic immune responses and efficient eradication of primary tumors, distant tumors, and tumor metastases. In addition, cancer stem cells (CSCs) in 4T1 and CT26 solid tumors were significantly inhibited by the immune functional DEVAIE NPs. Our work presents a facile method for the cellular generation of EV-biomimetic NPs and demonstrates that the integration of DEVs and AIE photosensitizers is a powerful direction for the production of clinical anticancer nanovaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据